Literature DB >> 26003329

Optimizing Quality and Efficiency of Healthcare Delivery in Hematopoietic Cell Transplantation.

Navneet S Majhail1.   

Abstract

Hematopoietic cell transplantation is a complex and resource intense procedure that can be associated with high risks of treatment failure due to disease relapse or complications. There also exists considerable variability among transplant centers with respect to the number of procedures performed, available resources and personnel, patient selection, transplant practices, and supportive care. Hematopoietic cell transplantation as a specialty has been a pioneer in incorporating the constructs of quality and efficiency routinely in patient care. However, several challenges still remain. Harmonization of data collection and reporting, use of innovative technological tools, evidence-based practice supported by clinical trials, better efforts towards care coordination and transition of care, and reduction of variation will facilitate these efforts and will lead to improved experience and outcomes for hematopoietic cell transplant recipients.

Entities:  

Mesh:

Year:  2015        PMID: 26003329     DOI: 10.1007/s11899-015-0264-3

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  18 in total

1.  What is value in health care?

Authors:  Michael E Porter
Journal:  N Engl J Med       Date:  2010-12-08       Impact factor: 91.245

2.  Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program.

Authors:  C Chabannon; D Pamphilon; C Vermylen; A Gratwohl; D Niederwieser; E McGrath; C Lamers; F Lanza; I Slaper-Cortenbach; A Madrigal; J Apperley
Journal:  Bone Marrow Transplant       Date:  2011-03-07       Impact factor: 5.483

Review 3.  Surviving the cure: long term followup of hematopoietic cell transplant recipients.

Authors:  N S Majhail; J Douglas Rizzo
Journal:  Bone Marrow Transplant       Date:  2013-01-07       Impact factor: 5.483

Review 4.  Racial disparities in hematopoietic cell transplantation in the United States.

Authors:  N S Majhail; S Nayyar; M E Burton Santibañez; E A Murphy; E M Denzen
Journal:  Bone Marrow Transplant       Date:  2011-11-07       Impact factor: 5.483

5.  Practice variation in physician referral for allogeneic hematopoietic cell transplantation.

Authors:  J Pidala; B M Craig; S J Lee; N Majhail; G Quinn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-06-18       Impact factor: 5.483

Review 6.  Referral to transplant center for hematopoietic cell transplantation.

Authors:  Navneet S Majhail; Madan Jagasia
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-26       Impact factor: 3.722

7.  Access to hematopoietic stem cell transplantation: effect of race and sex.

Authors:  Thomas V Joshua; J Douglas Rizzo; Mei-Jie Zhang; Parameswaran N Hari; Seira Kurian; Marcelo Pasquini; Navneet S Majhail; Stephanie J Lee; Mary M Horowitz
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

Review 8.  Allogeneic transplant physician and center capacity in the United States.

Authors:  Navneet S Majhail; Elizabeth A Murphy; Nancy A Omondi; Pam Robinett; James L Gajewski; C Fred LeMaistre; Dennis Confer; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

9.  Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative.

Authors:  Ellen M Denzen; Navneet S Majhail; Stacy Stickney Ferguson; Claudio Anasetti; Arthur Bracey; Linda Burns; Richard Champlin; Jeffrey Chell; Helen Leather; Michael Lill; Richard T Maziarz; Erin Medoff; Joyce Neumann; Kim Schmit-Pokorny; Edward L Snyder; Laura Wiggins; Deborah S Yolin Raley; Elizabeth A Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-15       Impact factor: 5.742

10.  Individual physician practice variation in hematopoietic cell transplantation.

Authors:  Stephanie J Lee; Steven Joffe; Andrew S Artz; Richard E Champlin; Stella M Davies; Madan Jagasia; Nancy A Kernan; Fausto R Loberiza; Robert J Soiffer; Mary Eapen
Journal:  J Clin Oncol       Date:  2008-03-31       Impact factor: 44.544

View more
  4 in total

Review 1.  Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.

Authors:  Minoo Battiwalla; André Tichelli; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-03       Impact factor: 5.742

Review 2.  National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report.

Authors:  Shahrukh K Hashmi; Christopher Bredeson; Rafael F Duarte; Stephanie Farnia; Susan Ferrey; Courtney Fitzhugh; Mary E D Flowers; James Gajewski; Dennis Gastineau; Melissa Greenwald; Madan Jagasia; Patricia Martin; J Douglas Rizzo; Kimberly Schmit-Pokorny; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

Review 3.  Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.

Authors:  Praveen Ramakrishnan Geethakumari; Dheepthi Perumal Ramasamy; Bhagirathbhai Dholaria; Jesús Berdeja; Ankit Kansagra
Journal:  Curr Hematol Malig Rep       Date:  2021-06-05       Impact factor: 3.952

4.  Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors.

Authors:  Navneet S Majhail; Elizabeth Murphy; Purushottam Laud; Jaime M Preussler; Ellen M Denzen; Beatrice Abetti; Alexia Adams; RaeAnne Besser; Linda J Burns; Jan Cerny; Rebecca Drexler; Theresa Hahn; Lensa Idossa; Balkrishna Jahagirdar; Naynesh Kamani; Alison Loren; Deborah Mattila; Joseph McGuirk; Heather Moore; Jana Reynolds; Wael Saber; Lizette Salazar; Barry Schatz; Patrick Stiff; John R Wingard; Karen L Syrjala; K Scott Baker
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.